Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Increased by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 13.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 15,592 shares of the medical research company’s stock after purchasing an additional 1,882 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Charles River Laboratories International were worth $3,071,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Tortoise Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares in the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Charles River Laboratories International during the third quarter valued at $32,000. Assetmark Inc. boosted its position in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. Whittier Trust Co. of Nevada Inc. increased its stake in Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after purchasing an additional 193 shares in the last quarter. Finally, Covestor Ltd raised its holdings in Charles River Laboratories International by 40.9% during the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock worth $65,000 after buying an additional 95 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CRL. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their target price for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Finally, Robert W. Baird reduced their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Trading Down 2.0 %

Shares of NYSE CRL opened at $190.46 on Friday. The stock has a market cap of $9.74 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 5.00 and a beta of 1.38. The business has a 50 day simple moving average of $194.35 and a 200 day simple moving average of $203.02. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 52 week low of $176.48 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.72 earnings per share. On average, research analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).